ALX Oncology Holdings Inc: Form 10-Q for the period ended Mar 31, 2024
Filed with the SEC on May 9, 2024 and accepted by EDGAR at May 9, 2024, 20:10 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2024-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 3 months2024-01-01 to 2024-03-31 | $31.7m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2024-01-01 to 2024-03-31 | −$37.8m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2024-01-01 to 2024-03-31 | $427.0k | us-gaap:InterestExpense |
| Net income | 3 months2024-01-01 to 2024-03-31 | −$35.6m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2024-01-01 to 2024-03-31 | −$0.71 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2024-01-01 to 2024-03-31 | −$0.71 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2024-01-01 to 2024-03-31 | 50,120,758 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months2024-01-01 to 2024-03-31 | −$37.9m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months2024-01-01 to 2024-03-31 | $148.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2024-03-31 | $14.0m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2024-03-31 | $167.9m | us-gaap:AssetsCurrent |
| Total assets | At period end2024-03-31 | $212.7m | us-gaap:Assets |
| Current liabilities | At period end2024-03-31 | $32.2m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2024-03-31 | $48.5m | us-gaap:Liabilities |
| Long-term debt | At period end2024-03-31 | $9.7m | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2024-03-31 | $0 | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | At period end2024-03-31 | $164.2m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0000950170-24-056953. Last ingested by Listed: Oct 24, 2026, 15:07 ET. Listed shows no prices and gives no investment advice.